Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) shares traded up 3.2% on Monday . The company traded as high as $1.68 and last traded at $1.61. 1,460 shares were traded during mid-day trading, a decline of 78% from the average session volume of 6,538 shares. The stock had previously closed at $1.56.
Wall Street Analyst Weigh In
Separately, HC Wainwright lowered shares of Adlai Nortye from a "buy" rating to a "neutral" rating in a report on Monday, June 2nd.
Check Out Our Latest Report on ANL
Adlai Nortye Trading Up 8.0%
The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.02. The business's fifty day moving average is $1.54 and its 200-day moving average is $1.88.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Recommended Stories
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access